PDCD12 Antibody

PDCD1, also known as PD-1 or CD279, is an immune-inhibitory receptor expressed on the surface of activated T cells. It plays a crucial role in regulating the immune system by preventing overactivation of T cells, which can lead to autoimmune diseases .

PDCD1 is a member of the immunoglobulin superfamily and contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). When PDCD1 binds to its ligands, PD-L1 (CD274) and PD-L2 (CD273), it transmits an inhibitory signal that reduces T cell proliferation and cytokine production .

This inhibitory signal is crucial for maintaining immune tolerance and preventing autoimmunity. However, in the context of cancer, the PD-1/PD-L1 pathway can be exploited by tumor cells to evade immune detection and destruction .

The discovery of the PD-1/PD-L1 pathway has led to the development of immune checkpoint inhibitors, which are a class of drugs designed to block this pathway and enhance the body’s immune response against tumors. These inhibitors have shown significant promise in treating various types of cancer, including melanoma, lung cancer, and renal cell carcinoma .

Mouse anti-human PDCD1 antibodies are monoclonal antibodies developed in mice that specifically target the human PDCD1 protein. These antibodies are used in research and clinical settings to study the PD-1/PD-L1 pathway and to develop new therapeutic strategies for cancer and autoimmune diseases .

Research on PDCD1 and its role in immune regulation continues to be a vibrant field. Scientists are exploring various aspects of PDCD1 signaling, its interactions with other immune checkpoints, and its potential as a therapeutic target for a wide range of diseases .